Skip to main content

Table 2 Cycle characteristics of patients undergoing the GnRHa-HRT protocol with or without luteal GnRHa administration

From: Additional single dose GnRH agonist during luteal phase support may improve live birth rate in GnRHa-HRT frozen–thawed embryo transfer cycle: a retrospective cohort study

Parameters

Luteal GnRHa group

(n = 179)

Control group

(n = 171)

p value

Endometrial thickness (mm)

11.1 ± 2.4

11.4 ± 2.6

0.164

Rate of ET day (%)

  

0.711

 Day 3 ET

58.1% (104/179)

56.1% (96/171)

 

 Day 5 ET

41.9% (75/179)

43.9% (75/171)

 

No. of transferred embryos

2.4 ± 0.8

2.5 ± 0.8

0.724

Quality of transferred embryos (%)

  

0.677

 Good quality only

69.3% (124/179)

67.8% (116/171)

 

 Good and poor quality

27.4% (49/179)

26.9% (46/171)

 

 Poor quality only

3.4% (6/179)

5.3% (9/171)

 

Rate of at least one top-quality embryo transferred (%)

83.8% (150/179)

83.6% (143/171)

0.965

Biochemical pregnancy rate (%)

64.8% (116/179)

46.2% (79/171)

< 0.001

Clinical pregnancy rate (%)

55.3% (99/179)

40.4% (69/171)

0.005

Implantation rate (%)

33.4 ± 36.6%

23.8 ± 33.6%

0.012

Ongoing pregnancy rate (%)

50.8% (91/179)

35.1% (60/171)

0.003

Live birth rate (%)

49.2% (88/179)

32.7% (56/171)

0.002

Miscarriage rate (%)

11.1% (11/99)

18.8% (13/69)

0.159

 Early miscarriage rate (%)

8.1% (8/99)

13.0% (9/69)

0.294

 Late miscarriage rate (%)

3.0% (3/99)

5.8% (4/69)

0.377

  1. Data are presented as the mean ± standard deviation or %
  2. GnRHa gonadotropin-releasing hormone agonist, HRT hormonal replacement therapy, ET embryo transfer